Details of the Drug Combination

General Information of Drug Combination (ID: DCRT120)

Drug Combination Name
BIO-300 Uracil mustard
Indication
Disease Entry Status REF
Astrocytoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Uracil mustard   DMHL7OB
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SNB-19
Zero Interaction Potency (ZIP) Score: 11.01
Bliss Independence Score: 11.44
Loewe Additivity Score: 10.23
LHighest Single Agent (HSA) Score: 15.56

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Uracil mustard
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [4]
Chronic myelogenous leukaemia 2A20.0 Approved [5]
Polycythemia vera 2A20.4 Approved [5]
Small lymphocytic lymphoma 2A82.0 Approved [5]
Uracil mustard Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Uracil mustard Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Increases ADR [7]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases ADR [7]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases ADR [7]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Increases ADR [7]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases ADR [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCTC2AV HL-60(TB) Investigative [1]
Anaplastic large cell lymphoma DCO9IG7 SR Investigative [1]
Childhood T acute lymphoblastic leukemia DCK1Z0P CCRF-CEM Investigative [1]
Chronic myelogenous leukemia DCSM05I K-562 Investigative [1]
Clear cell renal cell carcinoma DC2WOTU 786-0 Investigative [1]
Clear cell renal cell carcinoma DCD36IE TK-10 Investigative [1]
Glioblastoma DCM8K3V SNB-75 Investigative [1]
Glioma DC69TJ3 SF-295 Investigative [1]
Glioma DCHX2HL SF-268 Investigative [1]
Glioma DCUMYID SF-539 Investigative [1]
Papillary renal cell carcinoma DC8CIB0 ACHN Investigative [1]
Breast adenocarcinoma DCMNLLX MDA-MB-468 Investigative [8]
Carcinoma DCNY6M6 RXF 393 Investigative [8]
Colon adenocarcinoma DCG3C0E COLO 205 Investigative [8]
Colon carcinoma DC88QBP KM12 Investigative [8]
Invasive ductal carcinoma DCQEZGP HS 578T Investigative [8]
Adenocarcinoma DCNWRYK HT29 Investigative [9]
Adenocarcinoma DCHFU0K HCT116 Investigative [9]
High grade ovarian serous adenocarcinoma DCJD0ZV OVCAR-5 Investigative [9]
High grade ovarian serous adenocarcinoma DCGOJZY NCI\\/ADR-RES Investigative [9]
Large cell lung carcinoma DC2XQ4V NCI-H460 Investigative [9]
Lung adenocarcinoma DC02LQJ HOP-62 Investigative [9]
Lung adenocarcinoma DC5UODE EKVX Investigative [9]
Malignant melanoma DCNMFBQ LOX IMVI Investigative [9]
Malignant melanoma DC2V4N8 UACC62 Investigative [9]
Melanoma DCDRQ84 SK-MEL-2 Investigative [9]
Melanoma DCOL82I UACC-257 Investigative [9]
Minimally invasive lung adenocarcinoma DC89RYT NCI-H322M Investigative [9]
Mixed endometrioid and clear cell carcinoma DCFMH6V IGROV1 Investigative [9]
Ovarian serous cystadenocarcinoma DC5FV8H SK-OV-3 Investigative [9]
Pleural epithelioid mesothelioma DCPYXFO NCI-H226 Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 31 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
5 Uracil mustard FDA Label
6 Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
9 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.